IJTLD open Pub Date : 2025-05-12 eCollection Date: 2025-05-01 DOI: 10.5588/ijtldopen.24.0691

C Bourg, E Hodille, F Ader, O Dumitrescu, C Genestet

引用次数: 0

Does nutritional support contribute to mitigating the financial burden faced by TB-affected households? 营养支持是否有助于减轻受结核病影响家庭所面临的经济负担？

IJTLD open Pub Date : 2025-05-12 eCollection Date: 2025-05-01 DOI: 10.5588/ijtldopen.25.0079

D Inthavong, H Elsayed, P Keonakhone, V Seevisay, S Souksanh, S Suthepmany, P Siphanthong, P Sengmany, B Sisounon, J Sebert, M Yanagawa, F Morishita, N Nishikiori, T Yamanaka

{"title":"Does nutritional support contribute to mitigating the financial burden faced by TB-affected households?","authors":"D Inthavong, H Elsayed, P Keonakhone, V Seevisay, S Souksanh, S Suthepmany, P Siphanthong, P Sengmany, B Sisounon, J Sebert, M Yanagawa, F Morishita, N Nishikiori, T Yamanaka","doi":"10.5588/ijtldopen.25.0079","DOIUrl":"10.5588/ijtldopen.25.0079","url":null,"abstract":"Introduction: Costs for nutritional supplements and food were the main driver of costs incurred by TB-affected households in Lao People's Democratic Republic. This study assessed the impact of nutritional counselling and support on costs incurred by TB-affected households.Methods: We conducted longitudinal data collection of costs, income, and coping mechanisms of TB-affected households within an intervention study providing nutritional counselling and support for people diagnosed with TB and having a body mass index (BMI) <18.5 kg/m2. Data collection tools were adapted from the WHO's generic national TB patient cost survey questionnaire to fit a longitudinal study design. Costs were considered catastrophic when they exceeded 20% of annual household income before TB.Results: A total of 268 people treated for drug-susceptible TB were included in the analysis, and the prevalence of BMI <18.5 kg/m2 was 38%. The intervention group had significantly lower nutritional supplement costs and direct non-medical costs after TB diagnosis than the observation group. The intervention group had less progressive catastrophic costs (+23.3 percentage points) than the observation group (+30.9 percentage points).Conclusion: Nutritional counselling and support were significantly associated with a reduction in the proportion of TB-affected households facing catastrophic costs due to TB.","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"2 5","pages":"260-268"},"PeriodicalIF":0.0,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068456/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144061218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating disability, comorbidities and risk factors after TB treatment: an 18-24 month follow-up. 评估结核病治疗后的残疾、合并症和危险因素：18-24个月的随访。

IJTLD open Pub Date : 2025-05-12 eCollection Date: 2025-05-01 DOI: 10.5588/ijtldopen.25.0149

Y Sun, Y Lin, J E Golub, W Shu, J Jiang, Q Xu, Y Li, W Sun, Y Shi, J Liao, C Nie, C Liang, X Zhang, H Liu, Y Ma, R Zachariah, S D Berger, P Thekkur, D Nair, S Satyanarayana, A M V Kumar, A D Harries

{"title":"Evaluating disability, comorbidities and risk factors after TB treatment: an 18-24 month follow-up.","authors":"Y Sun, Y Lin, J E Golub, W Shu, J Jiang, Q Xu, Y Li, W Sun, Y Shi, J Liao, C Nie, C Liang, X Zhang, H Liu, Y Ma, R Zachariah, S D Berger, P Thekkur, D Nair, S Satyanarayana, A M V Kumar, A D Harries","doi":"10.5588/ijtldopen.25.0149","DOIUrl":"10.5588/ijtldopen.25.0149","url":null,"abstract":"Background: Several countries have developed national strategic plans to address post-TB disability and comorbidities. However, their feasibility and added value within routine programmatic settings remain undocumented.Methods: We followed up individuals who successfully completed TB treatment at 11 health facilities in China between 2022-2023. Within the programmatic setting, we assessed health status, on-going symptoms, comorbidities, risk factors and disability (measured by 6-minute walking test [6MWT]) 18-24 months after treatment completion.Results: Of 586 individuals who completed TB treatment, 503 (86%) were reassessed. Compared with end of TB treatment, there were significant increases in cough (11.0% versus 6.4%), untreated diabetes (3.2% versus <1.0%), high blood pressure (13.1% versus 8.9%), cigarette smoking (12.7% versus 5.2%) and excessive alcohol consumption (5.8% versus 1.2%). Other conditions remained similar with 27.0% still disabled (6MWT<400m). 78 (13%) patients died or were lost-to-follow-up, with risk factors at end of treatment including on-going symptoms (RR1.7, 95%CI 1.1-2.7), high blood pressure (RR2.3, 95%CI 1.2-4.1) and undernutrition (RR2.6, 95%CI 1.7-3.9). Nine patients had recurrent TB. Employment status remained unchanged, with 47.5% still unemployed 18-24 months later.Conclusions: TB survivors experienced substantial multimorbidity 18-24 months post-TB treatment. Health services must integrate long-term care strategies to address these ongoing health challenges.","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"2 5","pages":"299-305"},"PeriodicalIF":0.0,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068454/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144060287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neuromyelitis optica causing vision loss during TB treatment with sutezolid: evidence of aberrant immunity following infection. sutezolids治疗结核期间引起视力丧失的视神经脊髓炎：感染后异常免疫的证据。

IJTLD open Pub Date : 2025-05-12 eCollection Date: 2025-05-01 DOI: 10.5588/ijtldopen.25.0071

N A Glover, L Paramo, S Giangregorio, B Sukwana, S E Koele, S Charalambous, T Ngwanto, S Mashatole, D Mudzengi, N Heinrich, E M Svensson, F Abdullah, G Churchyard, R S Wallis

引用次数: 0

Decentralising TB services for children: quality of care is fundamental. 分散儿童结核病服务：护理质量至关重要。

IJTLD open Pub Date : 2025-05-12 eCollection Date: 2025-05-01 DOI: 10.5588/ijtldopen.24.0652

S M Graham, S Zawedde-Muyanja, M Palmer, R A Dlodlo

引用次数: 0

Assessing the impact of the TB response in Taiwan - the journey towards ending TB. 评估台湾结核病应对的影响-迈向终结结核病的旅程。

IJTLD open Pub Date : 2025-05-12 eCollection Date: 2025-05-01 DOI: 10.5588/ijtldopen.25.0103

P-C Chan, C-Y Chiang, P-H Lee, H-Y Lo, P-W Chu, J-J Chen, S Kato, M C B Raviglione

{"title":"Assessing the impact of the TB response in Taiwan - the journey towards ending TB.","authors":"P-C Chan, C-Y Chiang, P-H Lee, H-Y Lo, P-W Chu, J-J Chen, S Kato, M C B Raviglione","doi":"10.5588/ijtldopen.25.0103","DOIUrl":"10.5588/ijtldopen.25.0103","url":null,"abstract":"The incidence of TB in Taiwan declined by 62% from 2005 to 2023 (i.e., from 73/100,000 to 28/100,000). Here we review the past two decades of TB epidemiology, policy implementation, and outcomes, identifying gaps and solutions for domestic and global responses. An external review in 2024 assessed National TB Program progress towards the End TB goal, integrating feedback from an International Review Panel and a 2023 expert questionnaire. The findings informed Phase III (2026-2030) of the 'End TB by 2035 Project'. We present review materials, consensus recommendations, and follow-ups through 2024. In 2023, 64% of the TB cases were aged ≥ 65. TB incidence among those < 60 is projected to meet the End TB targets (<10/100,000) by 2035, while elimination (<1 per million) is expected among 0-14-year-olds. During 2005-2024, Taiwan universally adopted new diagnostic tools for drug-resistant TB, shorter regimens and user-friendly platforms for reporting and case management. Nationwide policy innovations included active case finding, and TB infection (TBI) treatment. Taiwan's consistent investment in TB reflects strong political commitment to End TB. Current challenges include aging, co-morbidities, high TB/TBI among foreign migrant workers and societal disparities, and we suggest that future efforts must leverage artificial intelligence, universal genotyping and greater inter-departmental collaboration.","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"2 5","pages":"251-259"},"PeriodicalIF":0.0,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068451/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144057503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

TB disability and multimorbidity at the onset of treatment in Kenya, Uganda, Zambia and Zimbabwe. 在肯尼亚、乌干达、赞比亚和津巴布韦，治疗开始时结核病致残和多重发病。

IJTLD open Pub Date : 2025-05-12 eCollection Date: 2025-05-01 DOI: 10.5588/ijtldopen.25.0171

S A Adakun, F M Banda, A Bloom, M Bochnowicz, J Chakaya, R Chimzizi, J P Dongo, C Duri, A D Harries, I Kathure, F N Kavenga, A M V Kumar, Y Lin, H Luzze, I Mbithi, M Mputu, A Mubanga, D Mudoola, D Nair, M Ngwenya, S Ntambi, P Owiti, A Owuor, P Thekkur, C Timire, E Tweyongyere, M YaDiul, R Zachariah

{"title":"TB disability and multimorbidity at the onset of treatment in Kenya, Uganda, Zambia and Zimbabwe.","authors":"S A Adakun, F M Banda, A Bloom, M Bochnowicz, J Chakaya, R Chimzizi, J P Dongo, C Duri, A D Harries, I Kathure, F N Kavenga, A M V Kumar, Y Lin, H Luzze, I Mbithi, M Mputu, A Mubanga, D Mudoola, D Nair, M Ngwenya, S Ntambi, P Owiti, A Owuor, P Thekkur, C Timire, E Tweyongyere, M YaDiul, R Zachariah","doi":"10.5588/ijtldopen.25.0171","DOIUrl":"10.5588/ijtldopen.25.0171","url":null,"abstract":"Background: We evaluated the practicality of integrating assessments on the burden of multimorbidity (including disability) and the effectiveness of referral pathways at the start of TB treatment across Kenya, Uganda, Zambia and Zimbabwe.Methods: A cohort study conducted within national TB programmes.Results: Assessments were conducted in 1,683 (92%) of 1,822 patients, taking a median time of 29 minutes (interquartile range:20-37). Regarding comorbidities, 567 (34%) had HIV infection, 141 (8%) had high-blood pressure, 101 (6%) had a mental health disorder and 65 (4%) had diabetes. The three most common risk factors were undernutrition in 622 (37%), probable alcohol dependence in 311 (18%) and cigarette smoking in 275 (16%). Disability (inability to walk 400m in six minutes) was observed in 316 of 1,545 (20%) patients. Overall, 1,305 (78%) patients had at least one comorbidity, risk factor and/or disability. Successful referral ranged from 85-100% for most conditions, except for those with occupational silica exposure and disability, where access to pulmonary rehabilitation services was suboptimal.Conclusions: A significant proportion of TB patients experienced multimorbidity, including disability, highlighting the need for integrated, patient-centered care and decentralized point-of-care services, particularly for pulmonary rehabilitation. This multi-country study offers a promising pathway towards achieving that goal.","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"2 5","pages":"291-298"},"PeriodicalIF":0.0,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068455/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144057505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Beyond a cure for TB: confronting the hidden burden of post-TB lung disease. 超越治愈结核病：直面结核后肺病的隐性负担。

IJTLD open Pub Date : 2025-05-12 eCollection Date: 2025-05-01 DOI: 10.5588/ijtldopen.25.0222

Y Kherabi, D R Silva, R Centis, L D'Ambrosio, G B Migliori

引用次数: 0

Patient and provider preferences for long-acting TB preventive therapy. 患者和提供者对长效结核病预防治疗的偏好。

IJTLD open Pub Date : 2025-05-12 eCollection Date: 2025-05-01 DOI: 10.5588/ijtldopen.24.0670

M Vermeulen, K K Scarsi, R Furl, H Sayles, M J Anderson, S Valawalkar, A Kadam, S R Cox, V Mave, M Barthwal, C Schutz, A Ward, J Dountio Ofimboudem, G Meintjes, S Rannard, A Owen, S Swindells

{"title":"Patient and provider preferences for long-acting TB preventive therapy.","authors":"M Vermeulen, K K Scarsi, R Furl, H Sayles, M J Anderson, S Valawalkar, A Kadam, S R Cox, V Mave, M Barthwal, C Schutz, A Ward, J Dountio Ofimboudem, G Meintjes, S Rannard, A Owen, S Swindells","doi":"10.5588/ijtldopen.24.0670","DOIUrl":"10.5588/ijtldopen.24.0670","url":null,"abstract":"Background: Tuberculosis preventive therapy (TPT) is critical for TB elimination but is underutilised. Long-acting (LA) TPT can potentially improve linkage to care, treatment adherence and outcomes.Methods: We conducted a cross-sectional in-person survey in two high TB burden countries to evaluate preferences and concerns about LA formulations for TPT. The survey compared oral pills to LA injections, implants, and microarray patches (MAPs). A parallel online survey of healthcare providers (HCPs) in low- and middle-income countries (LMICs) assessed the perceived feasibility of implementation. Data were summarised by descriptive statistics.Results: We recruited 409 patients (India, n = 209; South Africa, n = 200) and 94 HCP participants. The mean age of patients was 40 years; 65% were female, and 26% reported a history of TPT. Injectable LA-TPT was the most preferred modality, followed by pills, implants, and then MAPs. The majority (75%) expressed a strong willingness to try injectable LA-TPT. Among providers, 43% favoured injectable LA-TPT, 26% preferred oral pills, 18% implants, and 13% MAPs. Cost was a significant factor influencing HCPs' willingness to adopt LA-TPT, while potential inefficacy and prolonged side effects were the highest concerns of patient respondents.Conclusion: Injectable LA-TPT may be highly acceptable and feasible if concerns surrounding cost, effectiveness, and safety are addressed.","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"2 5","pages":"276-283"},"PeriodicalIF":0.0,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068448/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144050017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment success rate and time to culture conversion under a prospective BPaL cohort study. 在前瞻性BPaL队列研究中，治疗成功率和培养转化时间。

IJTLD open Pub Date : 2025-05-12 eCollection Date: 2025-05-01 DOI: 10.5588/ijtldopen.24.0524

E Burhan, J Sugiharto, M Soemarno, A Juan, Y Runtu, A Yuvensia, R Ramadhani, J Sabono, A Lailiyah, F Fenni, M Farikha, T Pakasi, I Pambudi, M Mbenga, I Koppelaar, V Mirtskhulava, F Wares, D Jerene, J K Jung, J S Lee, S Foraida, S Juneja, M Diachenko, A Gebhard

{"title":"Treatment success rate and time to culture conversion under a prospective BPaL cohort study.","authors":"E Burhan, J Sugiharto, M Soemarno, A Juan, Y Runtu, A Yuvensia, R Ramadhani, J Sabono, A Lailiyah, F Fenni, M Farikha, T Pakasi, I Pambudi, M Mbenga, I Koppelaar, V Mirtskhulava, F Wares, D Jerene, J K Jung, J S Lee, S Foraida, S Juneja, M Diachenko, A Gebhard","doi":"10.5588/ijtldopen.24.0524","DOIUrl":"10.5588/ijtldopen.24.0524","url":null,"abstract":"Background: In July 2022, Indonesia implemented the 6-month BPaL (bedaquiline, pretomanid, linezolid) regimen under operational research (OR) for selected drug-resistant tuberculosis patients. The study aimed to assess treatment success rate (TSR) and time to sputum culture conversion (TSCC).Methods: A prospective cohort study in fifteen sites between July 2022 and March 2023 enrolled patients with rifampicin-resistant/multidrug-resistant TB with additional fluoroquinolone resistance or intolerance/failures of previous second-line TB treatment. TSR was descriptively analysed, and Kaplan-Meier and Cox proportional-hazards analyses were used to evaluate TSCC.Results: A total of 87 patients were enrolled, 3 were withdrawn, and 84 completed treatment and had outcomes; 82 (97.6%) patients had successful treatment, 1 (1.2%) died, and 1 (1.2%) had failure. Overall, 61 (72.6%) patients had positive cultures at baseline, and favourable outcomes were included in the TSCC analysis; all 61 (100%) converted within the first 3 months (median 32 days of treatment, IQR 30.0-56.0). None of the six variables were statistically associated with conversion time.Conclusion: The Indonesian BPaL OR showed a highly promising TSR of 97.6%, with 100% sputum conversion within 3 months. The lack of observed statistical differences in the TSCC across variables shows that the BPaL treatment will be equally effective in all patient groups.","PeriodicalId":519984,"journal":{"name":"IJTLD open","volume":"2 5","pages":"284-290"},"PeriodicalIF":0.0,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12068447/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144039896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IJTLD open最新文献